Amicus Therapeutics (FOLD) Stock Highlights

9.8 | +0.72%

2024-12-21 02:54:34

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.

Statistics

Range Today

9.6 9.88

Volume Today 4.08M

Range 1 Year

9.02 14.57

Volume 1 Year 687.01M

Range 3 Year

5.91 14.57

Volume 3 Year 2.07B

Range 10 Year

4.41 25.39

Volume 10 Year 6.99B

Highlights

Market Capitalization 3.28B (mid)

Floating Shares 240.55M

Current Price 9.8

Price To Earnings -32.35

Price To Revenue 7.04

Price To Book 18.35

Earnings Per Share -0.34

Payout Ratio 0%

Performance

Latest +0.72%

1 Month +3.27%

3 Months -11.15%

6 Months +1.34%

1 Year -25.19%

3 Years -8.75%

5 Years +0.51%

10 Years +22.65%

Benchmarks

Market Capitalization

43 / 368

Gross Profits

22 / 278

Total Revenue

30 / 300

Total Rank

288 / 368

Free Cashflow

273 / 352

Performance 5 years

120 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.